Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 1/2008

01.02.2008 | Review

Molecular imaging as a tool for translating breast cancer science

verfasst von: David A Mankoff

Erschienen in: Breast Cancer Research | Sonderheft 1/2008

Einloggen, um Zugang zu erhalten

Abstract

The ability to measure biochemical and molecular processes underlies progress in breast cancer biology and treatment. These assays have traditionally been performed by analysis of cell culture or tissue samples. More recently, functional and molecular imaging has allowed the in vivo assay of biochemistry and molecular biology, which is highly complementary to tissue-based assays. This review briefly describes different imaging modalities used in molecular imaging and then reviews applications of molecular imaging to breast cancer, with a focus on translational work. It includes sections describing work in functional and physiological tumor imaging, imaging gene product expression, imaging the tumor microenvironment, reporter gene imaging, and cell labeling. Work in both animal models and human is discussed with an eye towards studies that have relevance to breast cancer treatment in patients.
Literatur
1.
Hutter H: Fluorescent reporter methods. Methods Mol Biol. 2006, 351: 155-173.PubMed
2.
Blasberg RG: Imaging update: new windows, new views. Clin Cancer Res. 2007, 13: 3444-3448.PubMed
3.
Mankoff DA: A definition of molecular imaging. J Nucl Med. 2007, 48: 18N-21NPubMed
4.
Mankoff DA, O'Sullivan F, Barlow WE, Krohn KA: Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol. 2007, 14: 398-405.PubMedPubMedCentral
5.
Benard F, Turcotte E: Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res. 2005, 7: 153-162.PubMedPubMedCentral
6.
Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA: Tumor receptor imaging. J Nucl Med. 2008,
7.
Welch DR: Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res. 2004, 6: 61-64.PubMed
8.
Bloch SH, Dayton PA, Ferrara KW: Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng Med Biol Mag. 2004, 23: 18-29.PubMed
9.
Bolan PJ, Nelson MT, Yee D, Garwood M: Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res. 2005, 7: 149-152.PubMedPubMedCentral
10.
Lehman CD, Schnall MD: Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res. 2005, 7: 215-219.PubMedPubMedCentral
11.
12.
Berger F, Gambhir SS: Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. Breast Cancer Res. 2001, 3: 28-35.PubMed
13.
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory Group: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007, 57: 75-89.PubMed
14.
Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD, ACRIN Trial 6667 Investigators Group: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007, 356: 1295-1303.PubMed
15.
Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE: Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology. 2006, 239: 361-374.PubMed
16.
Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM: Antiangiogenic and anti-tumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006, 24: 769-777.PubMed
17.
Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC: Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007, 25: 1-13.PubMed
18.
Sosnovik DE, Weissleder R: Emerging concepts in molecular MRI. Curr Opin Biotechnol. 2007, 18: 4-10.PubMed
19.
Morse DL, Galons JP, Payne CM, Jennings DL, Day S, Xia G, Gillies RJ: MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed. 2007, 20: 602-614.PubMed
20.
Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, Stopeck A: Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia. 2004, 6: 831-837.PubMedPubMedCentral
21.
Gillies RJ, Morse DL: In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng. 2005, 7: 287-326.PubMed
22.
Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H NMR spectroscopy – a pilot study at 4 T. Radiology. 2004, 233: 424-431.PubMed
23.
Mankoff DA, Eubank WB: Current and future use of positron emission tomography (PET) in breast cancer. J Mammary Gland Biol Neoplasia. 2006, 11: 125-136.PubMed
24.
Quon A, Gambhir SS: FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 2005, 23: 1664-1673.PubMed
25.
Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA: Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res. 2007, 13: 3460-3469.PubMed
26.
Cherry SR: The 2006 Henry N. Wagner Lecture: Of mice and men (and positrons) – advances in PET imaging technology. J Nucl Med. 2006, 47: 1735-1745.PubMed
27.
Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE: Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology. 2005, 234: 527-534.PubMed
28.
Alessio AM, Kinahan PE, Cheng PM, Vesselle H, Karp JS: PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am. 2004, 42: 1017-32. vii.PubMed
29.
Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, Butler J, Mehta R: Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res. 2005, 7: 279-285.PubMedPubMedCentral
30.
Mahmood U: Near infrared optical applications in molecular imaging. Earlier, more accurate assessment of disease presence, disease course, and efficacy of disease treatment. IEEE Eng Med Biol Mag. 2004, 23: 58-66.PubMed
31.
Henriquez NV, van Overveld PG, Que I, Buijs JT, Bachelier R, Kaijzel EL, Löwik CW, Clezardin P, Pluijm van der G: Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis. 2007, 24: 699-705.PubMed
32.
Mendelson EB: Problem-solving ultrasound. Radiol Clin North Am. 2004, 42: 909-18. vii.PubMed
33.
Ferrara K, Pollard R, Borden M: Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng. 2007, 9: 415-447.PubMed
34.
Huang SW, Kim K, Witte RS, Olafsson R, O'Donnell M: Inducing and imaging thermal strain using a single ultrasound linear array. IEEE Trans Ultrason Ferroelectr Freq Control. 2007, 54: 1718-1720.PubMed
35.
Brenner RJ, Parisky Y: Alternative breast-imaging approaches. Radiol Clin North Am. 2007, 45: 907-923. viii.PubMed
36.
Chodosh LA, Cardiff RD: In vivo imaging of the mammary gland: the shape of things to come. J Mammary Gland Biol Neoplasia. 2006, 11: 101-102.PubMed
37.
Kety SS: Basic principles for the quantitative estimation of regional cerebral blood flow. Res Publ Assoc Res Nerv Ment Dis. 1985, 63: 1-7.PubMed
38.
Rajendran JG, Mankoff DA: Positron emission tomography imaging of hypoxia and blood flow in tumors. Cancer Drug Discovery and Development: In vivo Imaging of Cancer. Edited by: Shields AF, Price P. 2006, Totowa, NJ: Humana Press, 47-71.
39.
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB: Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003, 44: 1806-1814.PubMed
40.
Barrett T, Brechbiel M, Bernardo M, Choyke PL: MRI of tumor angiogenesis. J Magn Reson Imaging. 2007, 26: 235-249.PubMed
41.
Choyke PL, Dwyer AJ, Knopp MV: Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003, 17: 509-520.PubMed
42.
Hylton N: Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006, 24: 3293-3298.PubMed
43.
Padhani AR, Leach MO: Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging. 2005, 30: 324-341.PubMed
44.
Strecker R, Scheffler K, Buchert M, Mross K, Drevs J, Hennig J: DCE-MRI in clinical trials: data acquisition techniques and analysis methods. Int J Clin Pharmacol Ther. 2003, 41: 603-605.PubMed
45.
Kiessling F, Morgenstern B, Zhang C: Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem. 2007, 14: 77-91.PubMed
46.
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P: Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol. 2003, 76 (Spec No 1): S87-91.PubMed
47.
Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW: A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res. 2006, 12: 281-288.PubMed
48.
Aliaga A, Rousseau JA, Cadorette J, Croteau E, van Lier JE, Lecomte R, Bénard F: A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol. 2007, 9: 144-150.PubMed
49.
Krak NC, Hoekstra OS, Lammertsma AA: Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging. 2004, 31 (Suppl 1): S103-111.PubMed
50.
Mankoff DA, Muzi M, Krohn KA: Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?. Mol Imaging Biol. 2003, 5: 281-285.PubMed
51.
Matsumura A, Isobe T, Takano S, Kawamura H, Anno I: Non-invasive quantification of lactate by proton MR spectroscopy and its clinical applications. Clin Neurol Neurosurg. 2005, 107: 379-384.PubMed
52.
Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR: In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed. 2006, 19: 504-512.PubMed
53.
Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T, Scarabino T: Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol. 2007, 17: 1651-1662.PubMed
54.
Leach MO: Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Res earch. Phys Med Biol. 2006, 51: R61-82.PubMed
55.
Mountford C, Lean C, Malycha P, Russell P: Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging. 2006, 24: 459-477.PubMed
56.
Mueller-Lisse UG, Scherr MK: Proton MR spectroscopy of the prostate. Eur J Radiol. 2007, 63: 351-360.PubMed
57.
Nelson SJ: Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003, 2: 497-507.PubMed
58.
Rosen Y, Lenkinski RE: Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics. 2007, 4: 330-345.PubMed
59.
Haddadin IS, McIntosh A, Meisamy S, Corum C, Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ: Metabolite quantification and high-field MRS in breast cancer. NMR Biomed. 2007,
60.
Tannock IF: Cell proliferation. The Basic Science of Oncology. Edited by: Tannock IF, Hill RP. 1992, New York: McGraw-Hill, 154-177.
61.
Cleaver JE: Thymidine metabolism and cell kinetics. Frontiers Biol. 1967, 6: 43-100.
62.
Mankoff DA, Shields AF, Link JM, Graham MM, Muzi M, Peterson LM, Eary JF, Krohn KA: Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med. 1999, 40: 614-624.PubMed
63.
Mankoff DA, Shields AF, Krohn KA: PET imaging of cellular proliferation. Radiol Clin North Am. 2005, 43: 153-167.PubMed
64.
Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ: Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998, 4: 1334-1336.PubMed
65.
Been LB, Elsinga PH, de Vries J, Cobben DC, Jager PL, Hoekstra HJ, Suurmeijer AJ: Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol. 2006, 32: 39-43.PubMed
66.
Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO: Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007, 34: 1339-1347.PubMed
67.
Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH: Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006, 8: 36-42.PubMed
68.
Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, Wallwiener D, Bares R, Dohmen BM: PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004, 31: 720-724.PubMed
69.
Blankenberg F, Ohtsuki K, Strauss HW: Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med. 1999, 43: 170-176.PubMed
70.
Wiele van de C, Lahorte C, Vermeersch H, Loose D, Mervillie K, Steinmetz ND, Vanderheyden JL, Cuvelier CA, Slegers G, Dierck RA: Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol. 2003, 21: 3483-3487.PubMed
71.
Schoenberger J, Bauer J, Moosbauer J, Eilles C, Grimm D: Innovative strategies in in vivo apoptosis imaging. Curr Med Chem. 2008, 15: 187-194.PubMed
72.
Tait JF, Smith C, Blankenberg FG: Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J Nucl Med. 2005, 46: 807-815.PubMedPubMedCentral
73.
Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD: Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007, 13: 443-450.PubMed
74.
Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol. 1995, 13: 1470-1477.PubMed
75.
Ishiwata K, Enomoto K, Sasaki T, Elsinga PH, Senda M, Okazumi S, Isono K, Paans AM, Vaalburg W: A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med. 1996, 37: 279-285.PubMed
76.
Hübner KF, Thie JA, Smith GT, Kabalka GW, Keller IB, Kliefoth AB, Campbell SK, Buonocore E: Positron emission tomography (PET) with 1-aminocyclobutane-1-[(11)C]carboxylic acid (1-[(11)C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging. 1998, 1: 165-173.PubMed
77.
Glunde K, Jacobs MA, Bhujwalla ZM: Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006, 6: 821-829.PubMed
78.
Stanwell P, Mountford C: In vivo proton MR spectroscopy of the breast. Radiographics. 2007, 27 (Suppl 1): S253-266.PubMed
79.
Groves AM, Win T, Haim SB, Ell PJ: Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 2007, 8: 822-830.PubMed
80.
Lupu R, Menendez JA: Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?. Endocrinology. 2006, 147: 4056-4066.PubMed
81.
Powles T, Murray I, Brock C, Oliver T, Avril N: Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007, 51: 1511-1520. discussion 1520–1521.PubMed
82.
Yu EY, Mankoff DA: Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn. 2007, 7: 659-672.PubMed
83.
Zheng QH, Stone KL, Mock BH, Miller KD, Fei X, Liu X, Wang J-Q, Glick-Wilson BE, Sledge GW, Hutchins GD: [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol. 2002, 29: 803-807.PubMed
84.
Jordan VC, Brodie AM: Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007, 72: 7-25.PubMed
85.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Baja-monde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792.PubMed
86.
Katzenellenbogen J: The pharmacology of steroid radiophar-maceuticals: specific and non-specific binding and uptake selectivity. Radiopharmaceuticals: Chemistry and Pharmacology. Edited by: Nunn A. 1992, New York: Marcel Dekker, 297-331.
87.
Katzenellenbogen JA, Welch MJ, Dehdashti F: The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997, 17: 1573-1576.PubMed
88.
Katzenellenbogen JA: Designing steroid receptor-based radio-tracers to image breast and prostate tumors. J Nucl Med. 1995, 36 (6 Suppl): 8S-13S.PubMed
89.
Rijks LJ, Busemann Sokole E, Stabin MG, de Bruin K, Janssen AG, van Royen EA: Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging. Eur J Nucl Med. 1998, 25: 40-47.PubMed
90.
Zielinski JE, Larner JM, Hoffer PB, Hochberg RB: The synthesis of 11 beta-methoxy-[16 alpha-123I] iodoestradiol and its interaction with the estrogen receptor in vivo and in vitro. J Nucl Med. 1989, 30: 209-215.PubMed
91.
Cummins CH: Radiolabeled steroidal estrogens in cancer research. Steroids. 1993, 58: 245-259.PubMed
92.
Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ: Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984, 25: 1212-1221.PubMed
93.
Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P: Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999, 26: 905-913.PubMed
94.
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA: Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006, 24: 2793-2799.PubMed
95.
Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA: Breast cancer: PET imaging of estrogen receptors. Radiology. 1988, 169: 45-48.PubMed
96.
Peterson LM, Mankoff DA, Lawton TJ, Yagle KJ, Schubert EK, Stekhova S, et al: Quantitative imaging of estrogen receptor expression of breast cancer with PET and [F-18']-fluorestradiol. J Nucl Med. 2008,
97.
Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ: Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995, 36: 1766-1774.PubMed
98.
Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ: Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001, 19: 2797-2803.PubMed
99.
Linden HM, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Schubert EK, Peterson LM, Krohn KA, Mankoff DA: Serial 18F-fluoroestradiol positron emission tomography (FES PET) measures estrogen receptor binding during endocrine therapy. Breast Cancer Res Treat. 2005
100.
Dehdashti F, McGuire AH, Brocklin HFV, Siegel BA, Andriole DP, Griffeth LK, Pomper MG, Katzenellenbogen JA, Welch MJ: Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-nonproges-terone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med. 1991, 32: 1532-1537.PubMed
101.
Jonson SD, Welch MJ: PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med. 1998, 42: 8-17.PubMed
102.
Verhagen A, Studeny M, Luurtsema G, Visser GM, De Goeij CC, Sluyser M, Nieweg OE, Ploeg Van der E, Go KG, Vaalburg W: Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol. 1994, 21: 941-952.PubMed
103.
Zhou D, Carlson KE, Katzenellenbogen JA, Welch MJ: Bromine- and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J Med Chem. 2006, 49: 4737-4744.PubMed
104.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25: 5287-5312.PubMed
105.
Bogdanov A, Kang HW, Querol M, Pretorius PH, Yudina A: Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo. Bioconjug Chem. 2007, 18: 1123-1130.PubMed
106.
Cai W, Chen K, He L, Cao Q, Koong A, Chen X: Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007, 34: 850-858.PubMed
107.
Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66: 4339-4348.PubMed
108.
Perik PJ, Lub-De Hooge MN, Gietema JA, Graaf van der WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG: Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006, 24: 2276-2282.PubMed
109.
Pnwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R, Mishra AK: Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther. 2005, 4: 854-860.PubMed
110.
Engfeldt T, Orlova A, Tran T, Bruskin A, Widström C, Karlström AE, Tolmachev V: Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging. 2007, 34: 722-733.PubMed
111.
Tolmachev V, Nilsson FY, Widström C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A: 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006, 47: 846-853.PubMed
112.
Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM: Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006, 47: 793-796.PubMedPubMedCentral
113.
Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004, 22: 701-706.PubMed
114.
Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM: 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007, 48: 1357-1368.PubMed
115.
de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, Graaf van der WT, Sluiter W, van Veldhuisen D, Suter T, Sleijfer D: (111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007, 43: 2046-2051.PubMed
116.
Dijkers E, Lub-de Hooge MN, Kosterink JG, Jager PL, Brouwers AH, Perk LR, van Dongen GA, de Vries EG: Characterization of 89Zf-trastuzumab for clinical HER2 immunoPET imaging. J Clin Oncol. 2007, 25: 140s-
117.
Achilefu S: Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res Treat. 2004, 3: 393-409.PubMed
118.
Artemov D, Mori N, Ravi R, Bhujwalla ZM: Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003, 63: 2723-2727.PubMed
119.
Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, Kim S, Cho EJ, Yoon HG, Suh JS, Cheon J: Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007, 13: 95-99.PubMed
120.
Liu J, Li J, Rosol TJ, Pan X, Voorhees JL: Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol. 2007, 52: 4739-4747.PubMed
121.
Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR: Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther. 2007, 6: 1230-1238.PubMed
122.
Winnard P, Raman V: Real time non-invasive imaging of receptor-ligand interactions in vivo. J Cell Biochem. 2003, 90: 454-463.PubMed
123.
Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H: Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res. 2007, 13: 2936-2945.PubMed
124.
Loo C, Lowery A, Halas N, West J, Drezek R: Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005, 5: 709-711.PubMed
125.
Hilger I, Leistner Y, Berndt A, Fritsche C, Haas KM, Kosmehl H, Kaiser WA: Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol. 2004, 14: 1124-1129.PubMed
126.
Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K: MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging. 2004, 22: 843-850.PubMed
127.
Copland JA, Eghtedari M, Popov VL, Kotov N, Mamedova N, Motamedi M, Oraevsky A: Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol. 2004, 6: 341-349.PubMed
128.
Sutherland R: Tumor hypoxia and gene expression. Acta Oncologica. 1998, 37: 567-574.PubMed
129.
Teicher Ba: Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13: 139-168.PubMed
130.
Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA: Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglu-cose positron emission tomography imaging. Clin Cancer Res. 2004, 10: 2245-2252.PubMed
131.
Padhani AR, Krohn KA, Lewis JS, Alber M: Imaging oxygenation of human tumours. Eur Radiol. 2007, 17: 861-872.PubMed
132.
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D: Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006, 82: 699-757.PubMed
133.
Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M: Patterns of {alpha}v{beta}3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med. 2008, 49: 255-259.PubMed
134.
Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M: Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006, 12: 3942-3949.PubMed
135.
Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993, 53: 977-984.PubMed
136.
Ciarmiello A, Vecchio SD, Silvestro P, Potenta M, Carriero M, Thomas R, Botti G, D'Aiuto G, Salvatore M: Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998, 16: 1677-1683.PubMed
137.
Hendrikse NH, de Vries EG, Franssen EJ, Vaalburg W, Graaf van der WT: In vivo measurement of [11C]verapamil kinetics in human tissues. Eur J Clin Pharmacol. 2001, 56: 827-829.PubMed
138.
Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett D, Bear HD, McCumiskey JF: Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol. 2007, 34: 823-831.PubMed
139.
Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD: Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005, 77: 503-514.PubMed
140.
Mohs AM, Lu ZR: Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv. 2007, 4: 149-164.PubMed
141.
Serganova I, Blasberg R: Reporter gene imaging: potential impact on therapy. Nucl Med Biol. 2005, 32: 763-780.PubMed
142.
Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, Gambhir SS: Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther. 2005, 12: 329-339.PubMed
143.
Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002, 2: 683-693.PubMed
144.
Ntziachristos V: Fluorescence molecular imaging. Annu Rev Biomed Eng. 2006, 8: 1-33.PubMed
145.
Blasberg RG, Tjuvajev JG: Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med. 1999, 43: 163-169.PubMed
146.
Gambhir SS, Barrio JR, Herschman HR, Phelps ME: Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol. 1999, 26: 481-490.PubMed
147.
Yaghoubi SS, Gambhir SS: Measuring herpes simplex virus thymidine kinase reporter gene expression in vitro. Nat Protoc. 2006, 1: 2137-2142.PubMed
148.
Blasberg RG: In vivo molecular-genetic imaging: multi-modality nuclear and optical combinations. Nucl Med Biol. 2003, 30: 879-888.PubMed
149.
Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G: Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther. 2004, 9: 436-442.PubMed
150.
Lyons SK: Advances in imaging mouse tumour models in vivo. J Pathol. 2005, 205: 194-205.PubMed
151.
Gilad AA, Winnard PT, van Zijl PC, Bulte JW: Developing MR reporter genes: promises and pitfalls. NMR Biomed. 2007, 20: 275-290.PubMed
152.
Zhang SJ, Wu JC: Comparison of imaging techniques for tracking cardiac stem cell therapy. J Nucl Med. 2007, 48: 1916-1919.PubMedPubMedCentral
153.
Acton PD, Zhou R: Imaging reporter genes for cell tracking with PET and SPECT. Q J Nucl Med Mol Imaging. 2005, 49: 349-360.PubMed
154.
Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML: Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther. 2002, 2: 55-66.PubMed
155.
Aboagye EO, Price PM: Use of positron emission tomography in anticancer drug development. Invest New Drugs. 2003, 21: 169-181.PubMed
156.
Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J: The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005, 11: 7967-7985.PubMed
157.
Aberle DR, Chiles C, Gatsonis C, Hillman BJ, Johnson CD, McClennan BL, Mitchell DG, Pisano ED, Schnall MD, Sorensen AG, American College of Radiology Imaging Network: Imaging and cancer: research strategy of the American College of Radiology Imaging Network. Radiology. 2005, 235: 741-751.PubMed
158.
Eubank WB, Mankoff DA: Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005, 35: 84-99.PubMed
Metadaten
Titel
Molecular imaging as a tool for translating breast cancer science
verfasst von
David A Mankoff
Publikationsdatum
01.02.2008
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe Sonderheft 1/2008
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2126

Weitere Artikel der Sonderheft 1/2008

Breast Cancer Research 1/2008 Zur Ausgabe

Review

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance

Viewpoint

The role of single nucleotide polymorphisms in breast cancer metastasis

Review

Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence

Review

Mechanisms of metastasis

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise